Surrogate marker profiles for genetic lesions in acute leukemias

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The basic hypothesis of surrogate marker profiles is that individual genetic lesions result in characteristic distortions of the cellular phenotype with some predictable consistency that can be exploited by sophisticated immunophenotyping. While cytogenetic and molecular aberrancies currently are accepted prognostic predictors in acute leukemias, single antigen expression and even antigenic profiles rarely impact on prognosis. However, increasingly, phenotypes are delineated which can serve as surrogates for underlying genetic aberrations of clinical importance. This development is of particular significance as antileukemic therapy becomes available that targets any component of the disturbed molecular pathways associated with these genetic lesions. This chapter will focus on established surrogate marker profiles, such as those for PML/RARα, AML1/ETO, FLT3-gene mutated acute lymphocytic leukemia (ALL), and BCR/ABLPOS ALL. As the list of therapeutic targets grows, the role of surrogate antigen profiles will grow, as they can predict for the efficacy of targeted approaches in lieu of expensive, time-consuming and not always accessible genetic analyses.

Original languageEnglish (US)
Pages (from-to)359-368
Number of pages10
JournalBest Practice and Research: Clinical Haematology
Volume23
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
Biomarkers
Phenotype
Antigens
Immunophenotyping
Aberrations
Cytogenetics
Genes
Therapeutics

Keywords

  • Genetic lesions
  • Immunophenotypes
  • Surrogate markers
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Cite this

Surrogate marker profiles for genetic lesions in acute leukemias. / Paietta, Elisabeth M.

In: Best Practice and Research: Clinical Haematology, Vol. 23, No. 3, 09.2010, p. 359-368.

Research output: Contribution to journalArticle

@article{994d579d30f74c1489a5eec4381d368a,
title = "Surrogate marker profiles for genetic lesions in acute leukemias",
abstract = "The basic hypothesis of surrogate marker profiles is that individual genetic lesions result in characteristic distortions of the cellular phenotype with some predictable consistency that can be exploited by sophisticated immunophenotyping. While cytogenetic and molecular aberrancies currently are accepted prognostic predictors in acute leukemias, single antigen expression and even antigenic profiles rarely impact on prognosis. However, increasingly, phenotypes are delineated which can serve as surrogates for underlying genetic aberrations of clinical importance. This development is of particular significance as antileukemic therapy becomes available that targets any component of the disturbed molecular pathways associated with these genetic lesions. This chapter will focus on established surrogate marker profiles, such as those for PML/RARα, AML1/ETO, FLT3-gene mutated acute lymphocytic leukemia (ALL), and BCR/ABLPOS ALL. As the list of therapeutic targets grows, the role of surrogate antigen profiles will grow, as they can predict for the efficacy of targeted approaches in lieu of expensive, time-consuming and not always accessible genetic analyses.",
keywords = "Genetic lesions, Immunophenotypes, Surrogate markers, Targeted therapy",
author = "Paietta, {Elisabeth M.}",
year = "2010",
month = "9",
doi = "10.1016/j.beha.2010.08.001",
language = "English (US)",
volume = "23",
pages = "359--368",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

TY - JOUR

T1 - Surrogate marker profiles for genetic lesions in acute leukemias

AU - Paietta, Elisabeth M.

PY - 2010/9

Y1 - 2010/9

N2 - The basic hypothesis of surrogate marker profiles is that individual genetic lesions result in characteristic distortions of the cellular phenotype with some predictable consistency that can be exploited by sophisticated immunophenotyping. While cytogenetic and molecular aberrancies currently are accepted prognostic predictors in acute leukemias, single antigen expression and even antigenic profiles rarely impact on prognosis. However, increasingly, phenotypes are delineated which can serve as surrogates for underlying genetic aberrations of clinical importance. This development is of particular significance as antileukemic therapy becomes available that targets any component of the disturbed molecular pathways associated with these genetic lesions. This chapter will focus on established surrogate marker profiles, such as those for PML/RARα, AML1/ETO, FLT3-gene mutated acute lymphocytic leukemia (ALL), and BCR/ABLPOS ALL. As the list of therapeutic targets grows, the role of surrogate antigen profiles will grow, as they can predict for the efficacy of targeted approaches in lieu of expensive, time-consuming and not always accessible genetic analyses.

AB - The basic hypothesis of surrogate marker profiles is that individual genetic lesions result in characteristic distortions of the cellular phenotype with some predictable consistency that can be exploited by sophisticated immunophenotyping. While cytogenetic and molecular aberrancies currently are accepted prognostic predictors in acute leukemias, single antigen expression and even antigenic profiles rarely impact on prognosis. However, increasingly, phenotypes are delineated which can serve as surrogates for underlying genetic aberrations of clinical importance. This development is of particular significance as antileukemic therapy becomes available that targets any component of the disturbed molecular pathways associated with these genetic lesions. This chapter will focus on established surrogate marker profiles, such as those for PML/RARα, AML1/ETO, FLT3-gene mutated acute lymphocytic leukemia (ALL), and BCR/ABLPOS ALL. As the list of therapeutic targets grows, the role of surrogate antigen profiles will grow, as they can predict for the efficacy of targeted approaches in lieu of expensive, time-consuming and not always accessible genetic analyses.

KW - Genetic lesions

KW - Immunophenotypes

KW - Surrogate markers

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=78649494841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649494841&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2010.08.001

DO - 10.1016/j.beha.2010.08.001

M3 - Article

VL - 23

SP - 359

EP - 368

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 3

ER -